# Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

> **NCT06757855** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 29 (estimated)

## Conditions studied

- CML,Blast Phase

## Interventions

- **DRUG:** Olverembatinib
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT06757855
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-26
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06757855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06757855, "Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06757855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*